Download sample of this report

CANCER TREATMENT OPTIONS AND MANAGEMENT
PERSONALIZED OPTIONS REPORT
ACUTE MYELOID LEUKEMIA - MYELODYSPLASTIC SYNDROMES: AML-MDS
FEMALE PATIENT
APRIL 6, 2011
1
Cancer Treatment Options and Management | www.ctoam.com Ph.778-999-5463
Personalized Options Plan: Patient
April 6, 2011
Cancer Treatment Options and Management Disclaimer:
The information and material provided in our reports, by consultation, or on our website and all
technical pages are strictly for educational purposes only.
This information it not intended as medical advice, or for prevention, diagnosis and treatment of
medical issues and should not be used as a substitute for professional medical advice, diagnosis,
or treatment. Please consult your health care professional before considering any new dietary,
diagnostics, or treatment options.
While we attempt to keep our information accurate, we cannot guarantee it is an accurate
representation of the latest information regarding cancer. If you have any concerns, please
contact the referenced research facility directly.
Cancer Treatment Options and Management Inc. is not responsible for the information found in
the reports, by consultation, on the website, or the referenced list.
Inclusion in any report, consultation, CTOAM’s website or reference list does not imply
endorsement by Cancer Treatment Options & Management Inc.
2
Cancer Treatment Options and Management | www.ctoam.com Ph.778-999-5463
Personalized Options Plan: Patient
April 6, 2011
TABLE OF CONTENTS:
SECTION
PAGE
INTRODUCTION
4
SECTION I: OVERVIEW OF AML
6
SECTION II: TREATMENT OPTIONS
14
SECTION III: TREATMENT MANAGEMENT
33
SECTION IV: CLINICAL TRIALS
51
APPENDIX A: IMPROVING BIOAVAILABILITY
62
APPENDIX B: REFERENCES
68
3
Cancer Treatment Options and Management | www.ctoam.com Ph.778-999-5463
Personalized Options Plan: Patient
April 6, 2011
INTRODUCTION:
This report is a meta-analysis of standard and cutting edge treatment options for Acute Myeloid
Leukemia (AML) with Myelodysplastic Syndromes (MDS).
In it you will find detailed information on the causes of this disease and most importantly, recent
advances in treatment that have the potential to provide a higher rate of success and longevity
than current standard treatments. It is important to note that by providing information on cutting
edge treatment options, CTOAM is not specifically recommending any course of treatment. Our
role is to research and present scientific, peer reviewed data that is important for you to know in
order to access the most advanced and beneficial treatment for your cancer that science and
medicine have to offer at this time.
The information provided in this report and any subsequent consultation is meant to be discussed
in full with your primary physician and treatment team. We have provided you with the
documentation and information you and your team need in order to be able to ensure that the
most promising new treatments can be easily explored and accessed by your treatment team. We
are also available to consult with your primary physician and treatment team in regards to
enhanced treatment options, clinical trial enrolment and the establishment of a nutraceutical diet
specific to your cancer and the underlying genes involved.
You will find details of some specific options for each of these key pieces of enhanced treatment
throughout this report.
In the case of clinical trials, CTOAM provides additional research and support services to clients
including a short list of the most beneficial clinical trials for you, contacting the facilities
involved to further assess the rightness of fit, and, upon your decision to proceed, arranging for
your involvement in the clinical trial.
Similarly, we will, upon request prepare a specific nutraceutical diet for you to ensure you are
consuming the most advantageous combinations of naturally occurring cancer fighting foods to
enhance the function of your physicians standard treatment. This also will serve to maintain high
levels of cancer fighting nutrients between treatment rounds and after treatment for the enhanced
prevention of reoccurrence.
These services streamline the process of engagement in complimentary treatments and make it
easier for you and your primary physician to spend your time on the administration of treatment
and on the most important task of rest and recovery.
The following is a brief overview of the contents of this report. A more detailed exploration of
each statement is provided (with referenced documentation attached) in the main body of this
report.
Cancer Treatment Options and Management | www.ctoam.com Ph.778-999-5463
4
Personalized Options Plan: Patient
April 6, 2011
Most cancers are perpetuated by cells that exhibit stem cell like properties: Cells that exist in a
dormant state until activated and have unlimited life spans. Cancer results when these cells
harbour mutations that cause them to constantly reproduce, metastasize, and recruit their own
blood supply. The ability of these to remain dormant protects them from standard chemotherapy
and radiation, which only target rapidly reproducing cells.
More effective recovery can often be achieved by combining multiple targeted approaches with
immune based therapies, which are also achieving significant results as single agents.
Due to the genetic complexity of individual AML-MRC cases, it is optimal to consider as many
mutated genes as possible. While many varied statistics can be found on the frequencies of these
genes found in various samples, it is best to consider complete molecular testing of the AML
blast cells.
While the prognosis of the standard treatment approach may appear dismal, clinical trials that
target AML initiating stem cells by inhibiting the cancer causing mutated genes are promising
significant improvements in long-term survival (Misaghian et al., 2009).
As you will see in Section IV on Clinical Trials, there are a number of very promising clinical
trials available for AML-MDS and these should be considered as part of the natural treatment
protocol for this form of cancer.
While clinical trials provide the basis for molecular targeted therapies, plant phytochemicals
(also known as: Nutraceuticals), can provide an additional means of gene regulation.The
characterization of nutraceutical-based gene regulation has identified four nutraceuticals as
single agents that can greatly inhibit AML stem cells when used in high doses.
While issues such as low bioavailability and rapid metabolism have previously prevented the
clinical application of these nutraceuticals, some of these issues have recently been resolved by
the use of synergistic combinations. These are outlined for you in Section III: Treatment
Management, and in Appendix A on Nutraceutical Bioavailability.
Specific combinations of nutraceuticals can result in greatly improved tumor-inhibiting activity
at much lower concentrations by improving bioavailability. Additional combinations of
nutraceuticals can be used to over-saturate or inhibit the mechanisms that break down and
remove the beneficial nutraceuticals, allowing tumor-inhibiting activity to occur at levels
achievable through oral administration. Furthermore, these targeted diets can also sensitize AML
cells to other treatment regimes.
It is clear from our research, that with a combination approach of proper dosing of nutraceuticals
and engagement in some promising clinical trials, options exist currently to provide those with a
diagnosis of AML with increased survival rates and, as the research indicates, in some cases, full
remission.
Cancer Treatment Options and Management | www.ctoam.com Ph.778-999-5463
5